@article{Evans:2020:10.7150/ntno.44712,
author = {Evans, RJ and Lavin, B and Phinikaridou, A and Chooi, KY and Mohri, Z and Wong, E and Boyle, JJ and Krams, R and Botnar, R and Long, NJ},
doi = {10.7150/ntno.44712},
journal = {Nanotheranostics},
pages = {184--194},
title = {Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque},
url = {http://dx.doi.org/10.7150/ntno.44712},
volume = {4},
year = {2020}
}

Download

TY  - JOUR
AB  - Overview: Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo.Aim: To develop a range of MRI contrast agents based on superparamagnetic iron oxide nanoparticles (SPIONs), and test them in a murine model of advanced atherosclerosis.Methods: Nanoparticles of four core sizes were synthesised by thermal decomposition and coated with poly(maleicanhydride-alt-1-octadecene) (PMAO), poly(ethyleneimine) (PEI) or alendronate, then characterised for core size, hydrodynamic size, surface potential and relaxivity. On the basis of these results, one candidate was selected for further studies. In vivo studies using 10 nm PMAO-coated SPIONs were performed in ApoE-/- mice fed a western diet and instrumented with a perivascular cuff on the left carotid artery. Control ApoE-/- mice were fed a normal chow diet and were not instrumented. Mice were scanned on a 3T MR scanner (Philips Achieva) with the novel SPION contrast agent, and an elastin-targeted gadolinium agent that was shown previously to enable visualisation of plaque burden. Histo
AU  - Evans,RJ
AU  - Lavin,B
AU  - Phinikaridou,A
AU  - Chooi,KY
AU  - Mohri,Z
AU  - Wong,E
AU  - Boyle,JJ
AU  - Krams,R
AU  - Botnar,R
AU  - Long,NJ
DO  - 10.7150/ntno.44712
EP  - 194
PY  - 2020///
SN  - 2206-7418
SP  - 184
TI  - Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque
T2  - Nanotheranostics
UR  - http://dx.doi.org/10.7150/ntno.44712
UR  - https://www.ntno.org/v04p0184.htm
UR  - http://hdl.handle.net/10044/1/80107
VL  - 4
ER  - 

Download